uracil has been researched along with Bladder Cancer in 75 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "Direct mechanical irritation by uracil calculi formed following feeding of 3% uracil in the diet to male rats produces severe papillary hyperplasia (papillomatosis, which is reversible) of bladder epithelium." | 7.70 | Expression and localization of ornithine decarboxylase in reversible papillomatosis induced by uracil in rat bladder. ( Fukushima, S; Kitamura, Y; Nomura, S; Otani, S; Otori, K; Takada, N; Yano, Y, 1998) |
| "Expression of rat urinary bladder cathepsin E in benign papillomatosis induced by uracil and various stages of N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)-induced carcinogenesis was investigated immunohistochemically." | 7.69 | Immunohistochemically demonstrated variation in expression of cathepsin E between uracil-induced papillomatosis and N-butyl-N-(4-hydroxybutyl)nitrosamine-induced preneoplastic and neoplastic changes in rat urinary bladder. ( Fukushima, S; Ichinose, M; Inoue, H; Masui, T; Miki, K; Tatematsu, M; Yamamoto, S; Yonezawa, S, 1996) |
| "The safety of prolonged administration of UFT in which tegafur and uracil were mixed in a ratio of 1:4 in molar fraction was studied in 44 cases of bladder cancer and 10 cases of renal cell carcinoma." | 7.67 | [Clinical experience of tegafur-uracil (UFT) against bladder cancer and renal cell carcinoma]. ( Fujioka, Y; Hirasawa, S; Ishii, Y; Ito, H; Lin, TT; Nakagami, Y; Ogawa, H; Tanaka, K; Tannawa, K; Yamada, N, 1987) |
| "UFT, a compound containing uracil and tegafur (a prodrug of 5-fluorouracil) in a 4:1 molar ratio, has been used in Japan for the treatment of and as adjuvant chemotherapy for bladder cancer." | 6.19 | UFT in bladder cancer. ( Hosaka, M; Kubota, Y; Noguchi, S, 1999) |
| "We evaluated 63 patients with superficial bladder cancer (pTa, pTl) who were treated with instillation of bleomycin +/- bacillus Calmette-Guerin (BCG) and administration of uraciltfutraful (UFT) for prophylaxis of tumor recurrence after transurethral resection (TUR)." | 5.07 | [Prophylactic combination therapy after TUR of superficial bladder cancer]. ( Adachi, K; Ao, T; Endo, T; Kawakami, T; Koshiba, K; Mashimo, S; Uchida, T; Yokoyama, E, 1993) |
| "To evaluate the effect of UFT, a mixture of ftorafur and uracil in a ratio of 1:4, in preventing postoperative recurrence of bladder cancer, we performed a randomized controlled study with a non-medication group as control." | 5.06 | [Prophylactic effect of UFT on the recurrence of bladder cancer]. ( Ejiri, S; Hisazumi, H; Kanda, S; Katsumi, T; Kitagawa, K; Mikawa, I; Miyagi, T; Naito, K; Nakamura, T; Saka, A, 1990) |
| " UFT (a compound of tegafur and uracil) is said to be effective for bladder cancer." | 4.80 | [Progress in oral anti-cancer drug therapy for urological cancer]. ( Akaza, H; Tsukamoto, S, 1999) |
| "In the present study, Tbx3, a member of the T-box family of transcription factors, was identified as an up-regulated gene by mRNA differential display in the regression (apoptosis) stage after uracil-induction of papillomatosis in the rat urinary bladder." | 3.73 | Tbx3 expression is related to apoptosis and cell proliferation in rat bladder both hyperplastic epithelial cells and carcinoma cells. ( Asamoto, M; Hokaiwado, N; Ito, A; Shirai, T; Takahashi, S, 2005) |
| "Totally 203 healthy volunteers and 67 patients with bladder cancer were investigated with caffeine as a metabolic probe." | 3.70 | Relationship between metabolic phenotype of N-acetylation and bladder cancer. ( Cui, X; Guo, R; Li, C; Wang, B; Xu, Z, 2000) |
| " In the first study, 3% uracil was fed for 4 weeks to cause urinary calculi and consequent hyperplasia and papillomatosis, both regressing after withdrawal of the insult." | 3.70 | Aberrant expression of p27(Kip1) is associated with malignant transformation of the rat urinary bladder epithelium. ( Asamoto, M; Kimoto, N; Nakanishi, M; Ogawa, K; Shirai, T; Takahashi, S, 2000) |
| "Direct mechanical irritation by uracil calculi formed following feeding of 3% uracil in the diet to male rats produces severe papillary hyperplasia (papillomatosis, which is reversible) of bladder epithelium." | 3.70 | Expression and localization of ornithine decarboxylase in reversible papillomatosis induced by uracil in rat bladder. ( Fukushima, S; Kitamura, Y; Nomura, S; Otani, S; Otori, K; Takada, N; Yano, Y, 1998) |
| "Differences between the reversible papillomatosis and preneoplastic lesions of the urinary bladder of rats were investigated in terms of cell proliferation and apoptosis after cessation of uracil administration." | 3.69 | Differences in cell proliferation and apoptosis between reversible and irreversible mucosal lesions associated with uracil-induced urolithiasis in N-butyl-N-(4-hydroxybutyl)nitrosamine-pretreated. ( Hirose, M; Imaida, K; Shibata, M; Shirai, T; Tagawa, Y; Takahashi, S, 1995) |
| "Expression of rat urinary bladder cathepsin E in benign papillomatosis induced by uracil and various stages of N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)-induced carcinogenesis was investigated immunohistochemically." | 3.69 | Immunohistochemically demonstrated variation in expression of cathepsin E between uracil-induced papillomatosis and N-butyl-N-(4-hydroxybutyl)nitrosamine-induced preneoplastic and neoplastic changes in rat urinary bladder. ( Fukushima, S; Ichinose, M; Inoue, H; Masui, T; Miki, K; Tatematsu, M; Yamamoto, S; Yonezawa, S, 1996) |
| " 5-Fluorouracil (5-FU) was effective against only one bladder cancer xenograft among 6 cancer xenografts tested." | 3.68 | [Comparative studies on the antitumor activity of fluorinated pyrimidine derivatives against human bladder, cervical and ovarian cancer xenografts in nude mice]. ( Adachi, S; Akaza, H; Ishitsuka, H; Kanazawa, K; Miwa, M; Nitta, K; Sekiguchi, F; Tokita, H, 1991) |
| "Five non-genotoxic chemicals previously demonstrated to be bladder cancer promoters in 36-week in vivo assays for carcinogenesis were reevaluated in a 20-week experiment in order to assess the summation influence of dietary uracil, a component of RNA, on the development of (pre)neoplastic lesions." | 3.68 | Summation effects of uracil and other promoters on epithelial lesion development in the F344 rat urinary bladder initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. ( Asamoto, M; de Camargo, JL; Fukushima, S; Kato, T; Shirai, T, 1991) |
| "The safety of prolonged administration of UFT in which tegafur and uracil were mixed in a ratio of 1:4 in molar fraction was studied in 44 cases of bladder cancer and 10 cases of renal cell carcinoma." | 3.67 | [Clinical experience of tegafur-uracil (UFT) against bladder cancer and renal cell carcinoma]. ( Fujioka, Y; Hirasawa, S; Ishii, Y; Ito, H; Lin, TT; Nakagami, Y; Ogawa, H; Tanaka, K; Tannawa, K; Yamada, N, 1987) |
| "Uracil is known to cause reversible urolithiasis and to induce papillomatosis in the urinary bladder of F344 rats." | 3.67 | Summation effect of uracil on the two-stage and multistage models of urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. ( Fukushima, S; Masui, T; Mutai, M; Shirai, T; Takahashi, S, 1988) |
| "UFT (a mixture of futraful and uracil) was administered orally to 15 cases of recurrent and superficial bladder cancer principally for more than 4 weeks at the doses of 300 or 600 mg per day." | 3.66 | [Clinical effect of UFT on bladder cancer]. ( Asahi, T; Kaneshige, T; Kumon, H; Matsumura, Y; Ohmori, H; Ozaki, Y; Tsushima, T; Yoshimoto, J, 1982) |
| "In the study of prostate cancer, neither a significant difference of non-recurrent rate nor of survival rate was seen between the two groups." | 2.69 | [Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group]. ( Akaza, H; Hattori, K; Ishikawa, S; Kawai, K; Kikuchi, K; Kobayashi, T; Koiso, K; Kondo, F; Manabe, F; Matsuki, K; Miyanaga, N; Noguchi, R; Shimazui, T; Suzuki, R; Takeshima, H; Tsuchiya, A; Uchida, K, 1998) |
| "In urinary bladder cancer, the combination chemotherapy with 5-FU and low-dose CDDP has been used as a radiosensitizer." | 2.40 | [Combination chemotherapy with 5-FU and low-dose CDDP for urogenital tumors]. ( Fujinami, K; Kubota, Y, 1999) |
| "Computed tomographic scan revealed the bladder tumors and swelling of the internal iliac lymph nodes." | 2.40 | [A case of urothelial carcinoma associated with penile metastasis]. ( Horinaga, M; Ikeuchi, K; Kosugi, M, 1999) |
| "Uracil was the most effective tumor promoter in our study and increased the incidence of papillomas (90%) and TCC (74%)." | 1.48 | Evaluation of Uracil, Sodium Ascorbate, and Rosiglitazone as Promoters of Urinary Bladder Transitional Cell Carcinomas in Male Sprague-Dawley Rats. ( Attalla, B; Bergholm, AM; Billger, M; Chadwick, KD; Chen, SJ; Czajkowski, M; Dorr, T; Foster, JR; Granaldi, K; Graziano, M; Haile, S; Janovitz, E; Mangipudy, R; Söderberg, M; Song, Y; Tirmenstein, M, 2018) |
| "Herein, we report a bladder cancer case with multiple metastases which were controlled by low-dose UFT." | 1.37 | [A case of marked efficacy of low-dose UFT against metastatic bladder cancer]. ( Arai, Y; Ito, A; Kuwahara, M; Nakano, O; Satoh, M, 2011) |
| "UFT is an anticancer agent consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (5-FU) combined with uracil in a molar ratio of 1: 4." | 1.35 | 5-Fluorouracil incorporated into the tissue RNA of human and rat bladder carcinoma after administration of 1-(2-tetrahydrofuryl)-5-fluorouracil combined with uracil. ( Fujimoto, K; Hirao, Y; Okajima, E; Ozono, S; Tsujimoto, S, 2008) |
| "She had a history of superficial bladder tumors which were treated with transurethral resection (TURBT)." | 1.34 | [Superficial bladder cancer with lung metastasis without local invasion: a case report]. ( Ao, T; Baba, S; Hirayama, T; Irie, A; Iwabuchi, K; Iwamura, M; Kudoh, O; Matsumoto, K; Uchida, T, 2007) |
| "The diagnosis was bladder cancer (TCC, G3, T4N3M1) from detailed examination." | 1.30 | [A case of untreatable progressive bladder carcinoma effectively treated by single administration of tegafur and uracil]. ( Goto, R; Ikeuchi, T; Kai, Y; Ota, M; Yoshikawa, H, 1998) |
| "Uracil (U) was provided through the diet in order to expand the population of initiated cells." | 1.29 | Absence of promoting potential of bracken fern (Pteridium aquilinum) in rat urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine and uracil. ( de Camargo, JL; de Oliveira, ML; Fukushima, S; Souza Rocha, N, 1995) |
| " Since she complained of olfactory anesthesia at 2 months of treatment, the dosage of UFT was reduced to 2 capsules daily and the drug was withdrawn after another 2 months of treatment." | 1.28 | [Complete remission of lung metastases of bladder tumor treated by small dosage of UFT: a case report]. ( Fukuoka, H; Nomura, S; Ogawa, T; Sakanishi, S; Takeda, M, 1991) |
| "Uracil was administered for 15, 10 or 5 weeks followed by BBN for 23 weeks, the total observation time being 40 weeks." | 1.28 | Lack of synergism in rat urinary tract carcinogenesis between prior uracil treatment and N-butyl-N-(4-hydroxybutyl)-nitrosamine administration. ( Asamoto, M; Fukushima, S; Ogiso, T; Okumura, M; Shirai, T, 1991) |
| "Uracil was administered during weeks 9-11 at a dietary level of 3." | 1.28 | Promoting effect of the peroxisome proliferator, clofibrate, but not di(2-ethylhexyl)phthalate, on urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. ( Asakawa, E; Fukushima, S; Hagiwara, A; Ogiso, T; Tamano, S, 1990) |
| "Uracil has been shown to cause a strong proliferative response in the urinary bladder epithelium of rats and mice through calculus formation and, consequently, acts as a strong promoter in bladder carcinogenesis." | 1.28 | Strong promoting activity by uracil on urinary bladder carcinogenesis and a possible inhibitory effect on thyroid tumorigenesis in rats initiated with N-methyl-N-nitrosourea. ( Cohen, SM; Garland, EM; Mann, AM; Masui, T, 1989) |
| "In the uracil-treated groups, transitional cell carcinomas developed in 76% of the females and 8% of the males." | 1.28 | Carcinogenicity of uracil, a nongenotoxic chemical, in rats and mice and its rationale. ( Asakawa, E; Fukushima, S; Kagawa, M; Shirai, T; Tanaka, H; Yamamoto, A, 1992) |
| "Contrary to bladder tumors, the incidence of renal pelvic and ureteric tumors was increased by this regimen." | 1.27 | Production of urinary tract tumors by co-administration of uracil and N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide in F344 rats. ( Croft, WA; Hayashida, S; Kamiryo, Y; Wang, CY, 1987) |
| "In Groups 1 to 5, urinary bladder tumors developed in 20 of 20, 13 of 20, 6 of 20, 14 of 20 and 6 of 20, respectively." | 1.27 | [Effect of UFT on urinary bladder tumors in rats induced by N-butyl-N-(4-hydroxybutyl)nitrosamine]. ( Babaya, K; Hirao, Y; Matsuki, H; Moriya, A; Nakatsuji, F; Okajima, E; Samma, S; Tabata, S; Watanabe, S; Yoshie, T, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (22.67) | 18.7374 |
| 1990's | 45 (60.00) | 18.2507 |
| 2000's | 8 (10.67) | 29.6817 |
| 2010's | 5 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tirmenstein, M | 1 |
| Janovitz, E | 1 |
| Dorr, T | 1 |
| Song, Y | 1 |
| Chen, SJ | 1 |
| Granaldi, K | 1 |
| Chadwick, KD | 1 |
| Mangipudy, R | 1 |
| Graziano, M | 1 |
| Attalla, B | 1 |
| Haile, S | 1 |
| Czajkowski, M | 1 |
| Foster, JR | 1 |
| Bergholm, AM | 1 |
| Billger, M | 1 |
| Söderberg, M | 1 |
| El-Naggar, M | 1 |
| Ebbing, E | 1 |
| Bijnsdorp, I | 1 |
| van den Berg, J | 1 |
| Peters, GJ | 1 |
| Nomi, H | 1 |
| Takahara, K | 1 |
| Minami, K | 1 |
| Maenosono, R | 1 |
| Matsunaga, T | 1 |
| Yoshikawa, Y | 1 |
| Tsujino, T | 1 |
| Hirano, H | 1 |
| Inamoto, T | 1 |
| Yamamoto, I | 1 |
| Tsuji, M | 1 |
| Kiyama, S | 1 |
| Azuma, H | 1 |
| Satoh, M | 1 |
| Nakano, O | 1 |
| Kuwahara, M | 1 |
| Ito, A | 2 |
| Arai, Y | 2 |
| Gamagedara, S | 1 |
| Kaczmarek, AT | 1 |
| Jiang, Y | 1 |
| Cheng, X | 2 |
| Rupasinghe, M | 1 |
| Ma, Y | 1 |
| DEREN, TL | 1 |
| WILSON, WL | 1 |
| WOODRUFF, MW | 1 |
| MURPHY, WT | 1 |
| HODSON, JM | 1 |
| Asamoto, M | 4 |
| Hokaiwado, N | 1 |
| Takahashi, S | 5 |
| Shirai, T | 15 |
| Ihlaseh, SM | 1 |
| de Oliveira, ML | 3 |
| Teràn, E | 1 |
| de Camargo, JL | 3 |
| Barbisan, LF | 1 |
| Hirayama, T | 1 |
| Matsumoto, K | 1 |
| Irie, A | 1 |
| Iwamura, M | 1 |
| Kudoh, O | 1 |
| Iwabuchi, K | 1 |
| Ao, T | 2 |
| Uchida, T | 2 |
| Baba, S | 1 |
| Tsujimoto, S | 1 |
| Fujimoto, K | 1 |
| Okajima, E | 4 |
| Ozono, S | 2 |
| Hirao, Y | 3 |
| Masuda, F | 2 |
| Tashiro, K | 1 |
| Machida, T | 1 |
| Shida, K | 1 |
| Yamanaka, H | 1 |
| Ito, Y | 1 |
| Shimazaki, J | 1 |
| Isaka, S | 1 |
| Yokokawa, M | 1 |
| Fukui, I | 1 |
| Kawai, H | 1 |
| Akimoto, M | 1 |
| Yoshida, K | 1 |
| Asahi, T | 1 |
| Matsumura, Y | 1 |
| Ozaki, Y | 1 |
| Yoshimoto, J | 1 |
| Kaneshige, T | 1 |
| Kumon, H | 1 |
| Tsushima, T | 1 |
| Ohmori, H | 1 |
| Yokoyama, E | 1 |
| Kawakami, T | 1 |
| Adachi, K | 1 |
| Mashimo, S | 1 |
| Endo, T | 1 |
| Koshiba, K | 1 |
| Shibata, M | 1 |
| Tagawa, Y | 3 |
| Imaida, K | 4 |
| Hirose, M | 1 |
| Shibata, MA | 3 |
| Takesada, Y | 1 |
| Iwata, H | 2 |
| Okumura, M | 4 |
| Fukushima, S | 21 |
| Kloth, MT | 1 |
| Gee, RL | 1 |
| Messing, EM | 1 |
| Swaminathan, S | 1 |
| Uwagawa, S | 2 |
| Saito, K | 1 |
| Okuno, Y | 1 |
| Kawasaki, H | 1 |
| Yoshitake, A | 1 |
| Yamada, H | 1 |
| Yamada, Y | 1 |
| Washida, H | 1 |
| Tozawa, K | 1 |
| Honma, H | 1 |
| Kang, K | 1 |
| Nakamoto, T | 2 |
| Igawa, M | 2 |
| Usui, T | 3 |
| Takeyama, M | 1 |
| Honjoh, M | 1 |
| Ohnishi, N | 1 |
| Ishikawa, Y | 1 |
| Sakaguchi, H | 1 |
| Hanai, J | 1 |
| Lina, BA | 1 |
| Rutten, AA | 1 |
| Woutersen, RA | 1 |
| Sano, M | 2 |
| Kubota, Y | 3 |
| Hosaka, M | 2 |
| Kondo, I | 1 |
| Yamamoto, S | 1 |
| Yonezawa, S | 1 |
| Ichinose, M | 1 |
| Miki, K | 1 |
| Masui, T | 6 |
| Inoue, H | 1 |
| Tatematsu, M | 1 |
| Ogawa, K | 3 |
| Sun, TT | 1 |
| Cohen, SM | 5 |
| Souza Rocha, N | 1 |
| Otori, K | 2 |
| Yano, Y | 2 |
| Takada, N | 2 |
| Lee, CC | 1 |
| Hayashi, S | 1 |
| Otani, S | 2 |
| Uzvolgyi, E | 1 |
| St John, MK | 1 |
| Arnold, L | 1 |
| Nomura, S | 2 |
| Kitamura, Y | 1 |
| Uchida, K | 2 |
| Takeshima, H | 1 |
| Kikuchi, K | 1 |
| Shimazui, T | 1 |
| Miyanaga, N | 1 |
| Kawai, K | 1 |
| Akaza, H | 3 |
| Tsuchiya, A | 1 |
| Noguchi, R | 1 |
| Hattori, K | 1 |
| Manabe, F | 1 |
| Matsuki, K | 1 |
| Suzuki, R | 1 |
| Ishikawa, S | 1 |
| Kondo, F | 1 |
| Kobayashi, T | 1 |
| Koiso, K | 3 |
| Goto, R | 1 |
| Yoshikawa, H | 1 |
| Ota, M | 1 |
| Ikeuchi, T | 1 |
| Kai, Y | 1 |
| Tsukamoto, S | 1 |
| Vieira de Oliveira, S | 1 |
| Viana de Camargo, JL | 1 |
| Cardoso, PR | 1 |
| Padovani, CR | 1 |
| Noguchi, S | 1 |
| Murai, T | 1 |
| Fujinami, K | 1 |
| Horinaga, M | 1 |
| Kosugi, M | 1 |
| Ikeuchi, K | 1 |
| Kimoto, N | 1 |
| Nakanishi, M | 1 |
| Yano, A | 1 |
| Hashimoto, K | 1 |
| Okuchi, T | 1 |
| Mizoguchi, H | 1 |
| Mutaguchi, K | 1 |
| Cui, X | 1 |
| Guo, R | 1 |
| Xu, Z | 1 |
| Wang, B | 1 |
| Li, C | 1 |
| Touyama, H | 1 |
| Hokama, S | 1 |
| Hatano, T | 2 |
| Ogawa, Y | 1 |
| Yoshida, O | 1 |
| Kakehi, Y | 1 |
| Nishio, Y | 1 |
| Tomoyoshi, T | 2 |
| Konami, T | 2 |
| Takenaka, I | 1 |
| Fujita, K | 1 |
| Hayashi, J | 1 |
| Hidaka, N | 1 |
| Sanda, M | 1 |
| Ohashi, N | 1 |
| Yajima, Y | 1 |
| Furukawa, Y | 1 |
| Kato, M | 1 |
| Samma, S | 2 |
| Sasaki, K | 1 |
| Hiramatsu, T | 1 |
| Babaya, K | 2 |
| Watanabe, S | 2 |
| Maruyama, Y | 1 |
| Tanaka, H | 1 |
| Asakawa, E | 2 |
| Kagawa, M | 1 |
| Yamamoto, A | 1 |
| Mori, Y | 1 |
| Torii, S | 1 |
| Kawashima, Y | 1 |
| Kobari, T | 1 |
| Hosobe, T | 1 |
| Nishijima, Y | 2 |
| Nemoto, R | 2 |
| Garland, EM | 3 |
| St John, M | 1 |
| Okamura, T | 2 |
| Smith, RA | 2 |
| Kanimoto, Y | 1 |
| Suzuki, Y | 1 |
| Miwa, Y | 1 |
| Akino, H | 1 |
| Isomatu, Y | 1 |
| Okada, K | 1 |
| Hasegawa, R | 1 |
| Mann, AM | 2 |
| Macatee, TL | 1 |
| Kato, T | 1 |
| Miwa, M | 1 |
| Sekiguchi, F | 1 |
| Tokita, H | 1 |
| Nitta, K | 1 |
| Adachi, S | 1 |
| Kanazawa, K | 1 |
| Ishitsuka, H | 1 |
| Fukuoka, H | 1 |
| Takeda, M | 1 |
| Ogawa, T | 1 |
| Sakanishi, S | 1 |
| Hinotsu, S | 1 |
| Tamano, S | 2 |
| Ito, M | 1 |
| Yamada, S | 1 |
| Ogiso, T | 2 |
| Naito, K | 1 |
| Hisazumi, H | 1 |
| Saka, A | 1 |
| Nakamura, T | 1 |
| Kanda, S | 1 |
| Mikawa, I | 1 |
| Ejiri, S | 1 |
| Miyagi, T | 1 |
| Katsumi, T | 1 |
| Kitagawa, K | 1 |
| Hagiwara, A | 1 |
| Oda, H | 1 |
| Seki, N | 1 |
| Nabeshima, S | 1 |
| Oda, T | 1 |
| Nishio, S | 1 |
| Yokoyama, M | 1 |
| Takeuchi, M | 1 |
| Matsumoto, A | 1 |
| Terado, T | 1 |
| Kadlubar, FF | 1 |
| Talaska, G | 1 |
| Butler, MA | 1 |
| Teitel, CH | 1 |
| Massengill, JP | 1 |
| Lang, NP | 1 |
| Nakano, E | 1 |
| Iwasaki, A | 1 |
| Seguchi, T | 1 |
| Sugao, H | 1 |
| Yoshioka, T | 1 |
| Tada, Y | 1 |
| Matsuda, M | 1 |
| Sonoda, T | 1 |
| Ito, N | 3 |
| Takayama, H | 1 |
| Konishi, T | 1 |
| Pak, K | 1 |
| Nakagami, Y | 1 |
| Lin, TT | 1 |
| Ito, H | 1 |
| Hirasawa, S | 1 |
| Tannawa, K | 1 |
| Fujioka, Y | 1 |
| Ogawa, H | 1 |
| Tanaka, K | 1 |
| Yamada, N | 1 |
| Ishii, Y | 1 |
| Sato, K | 1 |
| Miyazato, T | 1 |
| Saito, S | 1 |
| Kashiwabara, N | 1 |
| Igarashi, M | 1 |
| Koyama, Y | 1 |
| Hayakawa, M | 1 |
| Osawa, A | 1 |
| Mutai, M | 1 |
| Wang, CY | 1 |
| Kamiryo, Y | 1 |
| Hayashida, S | 1 |
| Croft, WA | 1 |
| Tabata, S | 1 |
| Nakatsuji, F | 1 |
| Yoshie, T | 1 |
| Moriya, A | 1 |
| Matsuki, H | 1 |
| Ikawa, E | 1 |
5 reviews available for uracil and Bladder Cancer
| Article | Year |
|---|---|
[Progress in oral anti-cancer drug therapy for urological cancer].
Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Drug Administration Sch | 1999 |
UFT in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Humans; Tegafur; | 1999 |
Calculi, precipitates and microcrystalluria associated with irritation and cell proliferation as a mechanism of urinary bladder carcinogenesis in rats and mice.
Topics: Animals; Carcinogens; Cell Division; Chemical Precipitation; Crystallization; Humans; Irritants; Mic | 1999 |
[Combination chemotherapy with 5-FU and low-dose CDDP for urogenital tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Combined Modality | 1999 |
[A case of urothelial carcinoma associated with penile metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Lymphati | 1999 |
9 trials available for uracil and Bladder Cancer
| Article | Year |
|---|---|
[Prophylactic combination therapy after TUR of superficial bladder cancer].
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic C | 1993 |
Prophylactic oral UFT therapy for superficial bladder cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1993 |
[Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group].
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineop | 1998 |
UFT in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Humans; Tegafur; | 1999 |
[Prophylactic effect of UFT in combination with intravesical chemotherapy on the recurrence of superficial bladder tumor].
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic C | 1992 |
A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer--intravesical thio-TEPA versus oral UFT.
Topics: Administration, Intravesical; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Proto | 1992 |
[A comparative clinical trial of UFT treatment and intravesical adriamycin instillation to prevent recurrence of superficial bladder cancer].
Topics: Administration, Intravesical; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; | 1992 |
[Prophylactic effect of UFT on the recurrence of bladder cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1990 |
[A comparative clinical trial of UFT medication and intravesical BCG in the recurrence of superficial bladder cancer. Study Group of UFT and BCG adjuvant therapy for bladder cancer].
Topics: Administration, Intravesical; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined | 1990 |
62 other studies available for uracil and Bladder Cancer
| Article | Year |
|---|---|
Evaluation of Uracil, Sodium Ascorbate, and Rosiglitazone as Promoters of Urinary Bladder Transitional Cell Carcinomas in Male Sprague-Dawley Rats.
Topics: Animals; Ascorbic Acid; Carcinogens; Carcinoma, Transitional Cell; Disease Models, Animal; Male; Rat | 2018 |
Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.
Topics: Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Combinations; Enzyme Inhibitors; Gene Express | 2014 |
[A CASE OF ADVANCED BLADDER NEUROENDOCRINE CARCINOMA (SMALL CELL CARCINOMA) SIGNIFICANTLY IMPROVED BY LOW DOSE OF ORAL TEGAFUR-URACIL].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemothera | 2015 |
[A case of marked efficacy of low-dose UFT against metastatic bladder cancer].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female | 2011 |
Validation study of urinary metabolites as potential biomarkers for prostate cancer detection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Case-Control Studies; Chromatography, | 2012 |
Use of 5-fluorouracil in treatment of bladder carcinomas.
Topics: Antineoplastic Agents; Carcinoma; Fluorouracil; Uracil; Urinary Bladder Neoplasms | 1960 |
The use of combination 5-fluorouracil and supervoltage irradiation therapy in advanced carcinoma of the urinary bladder--a preliminary report.
Topics: Carcinoma; Cell- and Tissue-Based Therapy; Fluorouracil; Humans; Multiple Myeloma; Plasma Cells; Ura | 1962 |
Tbx3 expression is related to apoptosis and cell proliferation in rat bladder both hyperplastic epithelial cells and carcinoma cells.
Topics: Animals; Apoptosis; Base Sequence; Cell Proliferation; Gene Expression; Gene Library; Hyperplasia; I | 2005 |
Chemopreventive property of dietary ginger in rat urinary bladder chemical carcinogenesis.
Topics: Animals; Apoptosis; Butylhydroxybutylnitrosamine; Cell Proliferation; Cell Transformation, Neoplasti | 2006 |
[Superficial bladder cancer with lung metastasis without local invasion: a case report].
Topics: Administration, Intravesical; Administration, Oral; Aged; Antineoplastic Agents; BCG Vaccine; Carcin | 2007 |
5-Fluorouracil incorporated into the tissue RNA of human and rat bladder carcinoma after administration of 1-(2-tetrahydrofuryl)-5-fluorouracil combined with uracil.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; | 2008 |
[Clinical effect of UFT on urogenital tumors].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone an | 1984 |
[Phase II study of UFT for malignant tumors of urinary organs].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Comb | 1984 |
[Clinical effect of UFT on bladder cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fema | 1982 |
Differences in cell proliferation and apoptosis between reversible and irreversible mucosal lesions associated with uracil-induced urolithiasis in N-butyl-N-(4-hydroxybutyl)nitrosamine-pretreated.
Topics: Animals; Apoptosis; Butylhydroxybutylnitrosamine; Carcinogens; Cell Division; Male; Microscopy, Elec | 1995 |
Progressive growth of rat bladder carcinomas after exposure to prolonged uracil-induced urolithiasis.
Topics: Animals; Carcinoma, Transitional Cell; Dinoprostone; Male; Nucleolus Organizer Region; Proliferating | 1994 |
Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells.
Topics: Acetylation; Adult; Alleles; Amines; Arylamine N-Acetyltransferase; Biomarkers; Caffeine; Cells, Cul | 1994 |
Lack of induction of epithelial cell proliferation by sodium saccharin and sodium L-ascorbate in the urinary bladder of NCI-black-Reiter (NBR) male rats.
Topics: Animals; Ascorbic Acid; Body Weight; Carcinogens; Cell Division; DNA; Epithelial Cells; Epithelium; | 1994 |
[Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
Topics: Administration, Intravesical; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; | 1994 |
[Successful inhibition of bladder tumor recurrence by oral administration of UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional | 1994 |
[Relationship between tissue concentrations of 5-FU and degeneration of tissues after UFT administration in patients with bladder tumor].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Middl | 1993 |
Effect of coffee drinking on cell proliferation in rat urinary bladder epithelium.
Topics: Animals; Body Weight; Cell Division; Cell Transformation, Neoplastic; Coffee; Drinking; Electrolytes | 1993 |
Epithelia hyperplasia in the renal papilla and pelvis but not the urinary bladder of male F344 rats associated with dietary sodium phosphates after uracil exposure.
Topics: Animals; Drug Interactions; Epithelium; Hyperplasia; Kidney Medulla; Kidney Neoplasms; Kidney Pelvis | 1993 |
Immunohistochemically demonstrated variation in expression of cathepsin E between uracil-induced papillomatosis and N-butyl-N-(4-hydroxybutyl)nitrosamine-induced preneoplastic and neoplastic changes in rat urinary bladder.
Topics: Animals; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma, Transitional Cell; Cathepsin E; Cathe | 1996 |
Analysis of differentiation-associated proteins in rat bladder carcinogenesis.
Topics: Animals; FANFT; Male; Membrane Glycoproteins; Membrane Proteins; Rats; Rats, Inbred F344; Saccharin; | 1996 |
Absence of promoting potential of bracken fern (Pteridium aquilinum) in rat urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine and uracil.
Topics: Animals; Butylhydroxybutylnitrosamine; Carcinogens; Male; Papilloma; Plants, Toxic; Rats; Rats, Wist | 1995 |
Reversibility and apoptosis in rat urinary bladder papillomatosis induced by uracil.
Topics: Animals; Apoptosis; Cyclin D1; Cyclins; DNA Fragmentation; Immunohistochemistry; Lewis Blood Group A | 1997 |
Frequent p53 mutations and occasional loss of chromosome 4 in invasive bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in B6D2F1 mice.
Topics: Animals; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma; Chromosome Deletion; Humans; Male; Mi | 1998 |
Expression and localization of ornithine decarboxylase in reversible papillomatosis induced by uracil in rat bladder.
Topics: Animals; Blotting, Northern; Blotting, Western; Cell Division; Immunohistochemistry; In Situ Hybridi | 1998 |
[A case of untreatable progressive bladder carcinoma effectively treated by single administration of tegafur and uracil].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Drug Administration Sc | 1998 |
Effects of uracil calculi on cell growth and apoptosis in the BBN-initiated Wistar rat urinary bladder mucosa.
Topics: Animals; Apoptosis; Butylhydroxybutylnitrosamine; Carcinogens; Cell Division; Hyperplasia; Male; Muc | 1999 |
Aberrant expression of p27(Kip1) is associated with malignant transformation of the rat urinary bladder epithelium.
Topics: Animals; Bromodeoxyuridine; Butylhydroxybutylnitrosamine; Cell Cycle Proteins; Cyclin D1; Cyclin E; | 2000 |
[Dihydropyrimidine dehydrogenase activity in urothelial cancer--influence of UFT administration on DPD activity].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase | 2001 |
Relationship between metabolic phenotype of N-acetylation and bladder cancer.
Topics: Acetylation; Adult; Caffeine; Female; Humans; Male; Middle Aged; Phenotype; Uracil; Urinary Bladder | 2000 |
[Primary signet ring cell carcinoma of the urinary bladder: a case report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Signet Ring Cell; Drug Combinations; Humans; Male; Tegafur; | 2001 |
[A effective combination preoperative intraarterial infusion chemotherapy and irradiation for advanced sigmoid colon cancer with bladder invasion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 1992 |
Carcinogenicity of uracil, a nongenotoxic chemical, in rats and mice and its rationale.
Topics: Animals; Carcinogens; Carcinoma, Transitional Cell; Female; Male; Mice; Mice, Inbred Strains; Neopla | 1992 |
[Effect of UFT on experimental spinal metastasis in the mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; FANFT; Female; Mice; Mice, Inbred C3H; Neop | 1992 |
Acrolein initiates rat urinary bladder carcinogenesis.
Topics: Acrolein; Animals; FANFT; Hyperplasia; Male; Rats; Rats, Inbred F344; Uracil; Urinary Bladder; Urina | 1992 |
[Thymidylate synthase inhibition and concentration of 5-fluorouracil after administration of UFT in human uroepithelial carcinomas].
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 1991 |
Timing effects of uracil-induced urolithiasis on amplification of second-stage promotion in rat bladder carcinogenesis.
Topics: Animals; Bicarbonates; Body Weight; Butylhydroxybutylnitrosamine; Carcinogens; Drug Administration S | 1991 |
Direct DNA sequencing of the rat neu oncogene transmembrane domain reveals no mutation in urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl)nitrosamine, N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide or N-methyl-N-nitrosourea.
Topics: Amino Acid Sequence; Animals; Base Sequence; Butylhydroxybutylnitrosamine; DNA, Neoplasm; FANFT; Mal | 1991 |
Summation effects of uracil and other promoters on epithelial lesion development in the F344 rat urinary bladder initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Topics: Animals; Ascorbic Acid; Body Weight; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Butylhydrox | 1991 |
[Comparative studies on the antitumor activity of fluorinated pyrimidine derivatives against human bladder, cervical and ovarian cancer xenografts in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Floxuridine; | 1991 |
[Complete remission of lung metastases of bladder tumor treated by small dosage of UFT: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Lung N | 1991 |
[Effect of UFT with high dose leucovorin for transplantable bladder tumor (MBT-2) in mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Drug Synergism; Leucovorin; Mi | 1991 |
Uracil-induced calculi and carcinogenesis in the urinary bladder of rats treated simultaneously with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Topics: Animals; Butylhydroxybutylnitrosamine; Cell Division; Dinoprostone; Drug Synergism; Male; Rats; Rats | 1991 |
Lack of synergism in rat urinary tract carcinogenesis between prior uracil treatment and N-butyl-N-(4-hydroxybutyl)-nitrosamine administration.
Topics: Animals; Body Weight; Butylhydroxybutylnitrosamine; Cocarcinogenesis; Kidney Neoplasms; Kidney Pelvi | 1991 |
Promoting effect of the peroxisome proliferator, clofibrate, but not di(2-ethylhexyl)phthalate, on urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Topics: Animals; Body Weight; Butylhydroxybutylnitrosamine; Carcinogens; Clofibrate; Diethylhexyl Phthalate; | 1990 |
Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites.
Topics: Acetylation; Arylamine N-Acetyltransferase; Biotransformation; Caffeine; Cytochrome P-450 Enzyme Sys | 1990 |
[Case report of a complete regression of para-aortic lymph node metastasis from bladder cancer by oral administration of UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional | 1989 |
Strong promoting activity by uracil on urinary bladder carcinogenesis and a possible inhibitory effect on thyroid tumorigenesis in rats initiated with N-methyl-N-nitrosourea.
Topics: Adenocarcinoma; Animals; Body Weight; Carcinogens; Carcinoma, Transitional Cell; Male; Methylnitroso | 1989 |
Cell proliferation induced by uracil-calculi and subsequent development of reversible papillomatosis in the rat urinary bladder.
Topics: Animals; Cell Division; Male; Microscopy, Electron, Scanning; Papilloma; Rats; Rats, Inbred F344; Ur | 1989 |
[Studies on 5-FU concentration in serum and bladder tumor tissue after oral administration of UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hu | 1986 |
[Clinical experience of tegafur-uracil (UFT) against bladder cancer and renal cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Trans | 1987 |
[Clinical studies of the treatment of bladder tumor and its effects--experience in 86 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Tr | 1988 |
Summation effect of uracil on the two-stage and multistage models of urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Topics: Animals; Body Weight; Butylated Hydroxyanisole; Butylhydroxybutylnitrosamine; Carcinoma, Transitiona | 1988 |
Effects of urinary crystals induced by acetazolamide, uracil, and diethylene glycol on urinary bladder carcinogenesis in N-butyl-N-(4-hydroxybutyl)nitrosamine-initiated rats.
Topics: Acetazolamide; Animals; Butylhydroxybutylnitrosamine; Crystallization; Dose-Response Relationship, D | 1988 |
Strong promoting activity of reversible uracil-induced urolithiasis on urinary bladder carcinogenesis in rats initiated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Topics: Animals; Butylhydroxybutylnitrosamine; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cocar | 1987 |
Production of urinary tract tumors by co-administration of uracil and N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide in F344 rats.
Topics: Animals; Body Weight; Carcinoma; Cocarcinogenesis; FANFT; Female; Hyperplasia; Kidney Pelvis; Rats; | 1987 |
[Effect of UFT on urinary bladder tumors in rats induced by N-butyl-N-(4-hydroxybutyl)nitrosamine].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Butylhydroxybutylnitrosamine; Drug Administ | 1985 |
Uracil-induced urolithiasis and the development of reversible papillomatosis in the urinary bladder of F344 rats.
Topics: Animals; Hyperplasia; Male; Microscopy, Electron; Papilloma; Rats; Rats, Inbred F344; Uracil; Urinar | 1986 |